European Pharmaceutical Review Issue 4 2020

Within this issue find articles on the complexities of sterility assurance, how to detect and eliminate the risk of NDMA contamination and the findings from a study involving a novel formulation of cannabinoids that has been developed to treat glioblastoma. Also included are articles on the opportunities blockchain provides for life science and healthcare businesses, as well as a discussion on how COVID-19 has impacted life sciences and biotech investment and its potential effect on investor behaviour as the pandemic subsides.


Find in the issue:

    The trials and tribulations of the medical devices and IVD regulations
    Paul Ranson, Morgan Lewis
    Developing a preventive vaccine regimen to tackle Ebola
    Johan Van Hoof, Janssen Vaccines
    Regenerative medicine: a manufacturing overview
    Maciej Nakoniecznik, University College London
    Overview of workflows and data approaches in bioproduction – an industry perspective
    Melanie Diefenbacher, Genedata
    A glimpse at how Novartis’ manufacturing and supply organisation responded to COVID-19
    Steffen Lang, Novartis
    Beyond compliance: why embracing the FMD can transform medicine supply chain thinking
    Sébastien Sliski, Zetes

The rest of this content is restricted - login or subscribe free to access

European Pharmaceutical Review Issue 5 2022Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • bi-monthly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here